GlassScriptPhysician profile
Kazem Seyed
NPI 1003801390
$836.86
in general payments reported to CMS, 2019-2025
18 companies · $77.07 in 2025
The $77.07 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $174 · 2020: $89.33 · 2021: $49.72 · 2022: $148 · 2023: $179 · 2024: $119 · 2025: $77.07.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $375.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $375.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $240.29 | 2022-2024 | Inpen Smart Insulin Delivery System, Minimed 780g |
| Amgen INC. | $109.17 | 2024-2025 | Tepezza |
| Novo Nordisk INC | $59.52 | 2019-2022 | |
| Abbvie INC. | $54.44 | 2020-2022 | |
| Lilly USA, LLC | $48.65 | 2019-2020 | |
| Dexcom, INC. | $41.41 | 2019 | |
| Xeris Pharmaceuticals, INC. | $40.62 | 2022-2024 | Recorlev |
| Valeritas, INC. | $37.60 | 2019 | |
| Mannkind Corporation | $29.38 | 2019 | |
| Insulet Corporation | $28.96 | 2019-2024 | Omnipod |
| Rhythm Pharmaceuticals, INC. | $28.40 | 2024 | Imcivree |
| Bayer Healthcare Pharmaceuticals INC. | $25.51 | 2022 | |
| Horizon Therapeutics Plc | $18.13 | 2021 | |
| Cequr Corporation | $17.46 | 2023 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $15.07 | 2019 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.49 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.36 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $13.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kazem Seyed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.